2024. Bimekizumab Versus Secukinumab Continuous Maintenance of PASI 90 and PASI 100 Responses through One Year in Patients with Moderate to Severe Plaque Psoriasis: Post-HOC Results from the BE RADIANT Phase 3b Trial. SKIN The Journal of Cutaneous Medicine. 8, 2 (Mar. 2024), s403. DOI:https://doi.org/10.25251/skin.8.supp.403.